271 related articles for article (PubMed ID: 22084000)
1. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis.
Tan Y; Yin P; Tang L; Xing W; Huang Q; Cao D; Zhao X; Wang W; Lu X; Xu Z; Wang H; Xu G
Mol Cell Proteomics; 2012 Feb; 11(2):M111.010694. PubMed ID: 22084000
[TBL] [Abstract][Full Text] [Related]
2. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
[TBL] [Abstract][Full Text] [Related]
3. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients.
Zeng J; Huang X; Zhou L; Tan Y; Hu C; Wang X; Niu J; Wang H; Lin X; Yin P
Sci Rep; 2015 Nov; 5():16101. PubMed ID: 26526930
[TBL] [Abstract][Full Text] [Related]
5. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
6. Identification of 1-Methylnicotinamide as a specific biomarker for the progression of cirrhosis to hepatocellular carcinoma.
Zhang S; Tuo P; Ji Y; Huang Z; Xiong Z; Li H; Ruan C
J Cancer Res Clin Oncol; 2024 Jun; 150(6):310. PubMed ID: 38890166
[TBL] [Abstract][Full Text] [Related]
7. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus.
Cong M; Ou X; Huang J; Long J; Li T; Liu X; Wang Y; Wu X; Zhou J; Sun Y; Shang Q; Chen G; Ma H; Xie W; Piao H; Yang Y; Gao Z; Xu X; Tan Z; Chen C; Zeng N; Wu S; Kong Y; Liu T; Wang P; You H; Jia J; Zhuang H
OMICS; 2020 Jul; 24(7):415-423. PubMed ID: 32522092
[TBL] [Abstract][Full Text] [Related]
8. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry.
Zeng J; Yin P; Tan Y; Dong L; Hu C; Huang Q; Lu X; Wang H; Xu G
J Proteome Res; 2014 Jul; 13(7):3420-31. PubMed ID: 24853826
[TBL] [Abstract][Full Text] [Related]
10. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
[No Abstract] [Full Text] [Related]
12. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
Han J; Qin WX; Li ZL; Xu AJ; Xing H; Wu H; Zhang H; Wang MD; Li C; Liang L; Quan B; Yan WT; Shen F; Wu MC; Yang T
Clin Chim Acta; 2019 Jan; 488():68-75. PubMed ID: 30389456
[TBL] [Abstract][Full Text] [Related]
13. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
[TBL] [Abstract][Full Text] [Related]
14. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel biomarkers of hepatocellular carcinoma by high-definition mass spectrometry: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry and desorption electrospray ionization mass spectrometry imaging.
Nagai K; Uranbileg B; Chen Z; Fujioka A; Yamazaki T; Matsumoto Y; Tsukamoto H; Ikeda H; Yatomi Y; Chiba H; Hui SP; Nakazawa T; Saito R; Koshiba S; Aoki J; Saigusa D; Tomioka Y
Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1(Suppl 1):e8551. PubMed ID: 31412144
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic Characterization Analysis of Human Hepatocarcinoma by Urine Metabolomics Approach.
Liang Q; Liu H; Wang C; Li B
Sci Rep; 2016 Jan; 6():19763. PubMed ID: 26805550
[TBL] [Abstract][Full Text] [Related]
17. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
[TBL] [Abstract][Full Text] [Related]
18. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated serum metabolites in staging of hepatocellular carcinoma.
Wang W; Lv J; Chen N; Lou B; Mao W; Wang P; Chen Y
Clin Biochem; 2018 Nov; 61():7-11. PubMed ID: 30195484
[TBL] [Abstract][Full Text] [Related]
20. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
